FDA Grants Accelerated Approval to Olaratumab for Treatment of Advanced Soft-Tissue Sarcoma

The U.S. Food and Drug Administration (FDA) granted accelerated approval to olaratumab in combination with doxorubicin to treat adults with certain types of soft-tissue sarcoma...


Using Watson to Analyze Genomic Data to Personalize Treatment for Patients With Cancer

Three years ago, IBM’s Watson supercomputer was best known for defeating two former champions on the TV game show Jeopardy! Today, it is grabbing headlines for...

Gynecologic Cancers
Issues in Oncology

The FDA Urges Physicians and Patients to Forgo Ovarian Cancer Screening Tests

In a Safety Communication directed at women and physicians, the U.S. Food and Drug Administration (FDA) alerted women “about the risks associated with the use of tests...


More Top Stories

Lung Cancer

Luis G. Paz-Ares, MD, PhD, on NSCLC: Results from the LUX-Lung 7 Trial (Spanish Language Version)

Lung Cancer

Phase III Trial Finds No Survival Benefit of Adding Ipilimumab to Etoposide/Platinum in Newly Diagnosed Extensive-Stage SCLC

In a phase III trial (CA184-156) reported in the Journal of Clinical Oncology by Martin Reck, MD, PhD, of LungenClinic Grosshansdorf, Germany, and colleagues, the addition of the anti–CTLA-4 (cytotoxic T-lymphocyte–associated protein 4) checkpoint inhibitor ipilimumab (Yervoy) to...


Study Finds Nivolumab Improves Survival vs Standard Therapy in Recurrent Squamous Cell Carcinoma of the Head and Neck

In the phase III CheckMate 141 trial reported in The New England Journal of Medicine, Ferris et al found that nivolumab (Opdivo) increased overall survival vs standard therapies in patients with recurrent platinum-refractory squamous cell carcinoma of the head and neck.

Study Details

In this...

Prostate Cancer

Anders Widmark, MD, PhD, on Intermediate-Risk Prostate Cancer: Results From the HYPO-RT-PC Trial

Paul Jacobsen, PhD, Named Associate Director of National Cancer Institute Healthcare Delivery Research Program

Paul Jacobsen, PhD, has been named Associate Director of the National Cancer Institute (NCI) Division of Cancer Control and Population Science’s Healthcare Delivery Research Program. 

In this position, he will be leading a team at the NCI whose mission is to serve as a catalyst for the field of...

Issues in Oncology
Supportive Care
Palliative Care

Why Care About the Caregivers?

Caregivers of patients with cancer provide invaluable health-care services, but they are an underserved and undervalued group, with many unmet needs. Early palliative care may provide important benefits to these often tireless individuals, according to J. Nicholas Dionne-Odom, PhD, RN, ACHPN, of...

Investigational Immunotherapy Appears Safe and Somewhat Active in Advanced Melanoma

The investigational immunotherapeutic IMC-20D7S was found to be well tolerated and somewhat active in patients with advanced melanoma, including one complete response, according to the results of a phase I/Ib trial reported by Khalil et al in Clinical Cancer Research. 

IMD-20D7S is a...

Solid Tumors
Palliative Care

Philippe Rochigneux, MD, on Solid Tumors: Use of Chemotherapy Near the End of Life

Breast Cancer

Clinical Trials Actively Recruiting Patients With Early Breast Cancer


Study Title: Pilot Trial of an Implantable Microdevice for in Vivo Drug Sensitivity Testing in Patients With Early-Stage, HER2-Positive, or Triple-Negative Breast Cancer Receiving Neoadjuvant Therapy

Study Type: Pilot/interventional/single-group assignment

Study Sponsor and...


ESMO 2016: Clinical Benefit Demonstrated With Everolimus and Pasireotide LAR Alone or in Combination in Advanced Lung and Thymic Carcinoids

In patients with advanced lung or thymus carcinoid receiving everolimus, pasireotide LAR, or the combination of the two drugs, statistically significant positive impact was seen on proportion of patients’ progression-free rate at 9 months (primary endpoint) in all three arms, more relevant in ...

click me